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First published July 8, 2014; doi:10.1152/ajpendo.00643.2013.—To
investigate whether thyroid hormone (TH) interacts with the sympa-
thetic nervous system (SNS) to modulate bone mass and structure, we
studied the effects of daily T3 treatment in a supraphysiological dose
for 12 wk on the bone of young adult mice with chronic sympathetic
hyperactivity owing to double-gene disruption of adrenoceptors that
negatively regulate norepinephrine release, 2A-AR, and 2C-AR
(2A/2C-AR/ mice). As expected, T3 treatment caused a generalized
decrease in the areal bone mineral density (aBMD) of WT mice
(determined by DEXA), followed by deleterious effects on the tra-
becular and cortical bone microstructural parameters (determined by
CT) of the femur and vertebra and on the biomechanical properties
(maximum load, ultimate load, and stiffness) of the femur. Surpris-
ingly, 2A/2C-AR/ mice were resistant to most of these T3-induced
negative effects. Interestingly, the mRNA expression of osteoprote-
gerin, a protein that limits osteoclast activity, was upregulated and
downregulated by T3 in the bone of 2A/2C-AR/ and WT mice,
respectively. 1-AR mRNA expression and IGF-I serum levels, which
exert bone anabolic effects, were increased by T3 treatment only in
2A/2C-AR/ mice. As expected, T3 inhibited the cell growth of
calvaria-derived osteoblasts isolated from WT mice, but this effect
was abolished or reverted in cells isolated from KO mice. Collec-
tively, these findings support the hypothesis of a TH-SNS interaction
to control bone mass and structure of young adult mice and suggests
that this interaction may involve 2-AR signaling. Finally, the present
findings offer new insights into the mechanisms through which TH
regulates bone mass, structure, and physiology.
thyroid hormone; sympathetic nervous system; bone; -adrenocep-
tors; -adrenoceptors
THYROID HORMONE (TH) is essential for normal bone develop-
ment, maturation, and metabolism. Hypothyroidism retards
bone growth and slows bone turnover (3), whereas thyrotoxi-
cosis is frequently associated with accelerated bone develop-
ment and metabolism and decreased bone mass (43). Histo-
morphometric studies indicate that thyrotoxicosis increases
both osteoblastic and osteoclastic activities, but the latter
predominates. As a result, bone turnover is accelerated, favor-
ing bone resorption, a negative balance of calcium, and bone
loss (26, 41). Although the negative effects of overt thyrotox-
icosis to bone mass and turnover are well known, the mecha-
nisms by which TH promotes its effects are less clear. TH can
affect the skeleton indirectly through changes in other hor-
mones, e.g., growth hormone and IGF-I (31, 33), but in vitro
studies show that 3,3=,5-triiodo-L-thyronine (T3) also acts di-
rectly in bone cells, modifying their proliferation, differentia-
tion and/or expression of several bone-related genes (27, 39,
69, 70). It is generally accepted that most T3 actions are
mediated by its nuclear receptors, which were shown to be
expressed in osteoblasts (70), osteoclasts (1), and chondro-
blasts (4).
Recently, the sympathetic nervous system (SNS) was iden-
tified as an important and potent regulator of bone metabolism
(17, 61). A series of studies suggest that the SNS negatively
regulates bone formation and positively regulates bone resorp-
tion via 2-adrenoceptor (2-AR) signaling, which is expressed
in osteoblasts. Administration of propranolol, a -blocker, and
isoproterenol, a -agonist, was demonstrated to increase and
decrease bone mass, respectively, in adult animals (8, 10, 60).
The role of the SNS in controlling bone mass was supported by
a high-bone mass (HBM) phenotype in an animal model of low
SNS activity, a mouse deficient for dopamine -hydroxylase
(DbH/), the step-limiting enzyme responsible for catechol-
amine synthesis (10, 46). A more precise role of -adrenergic
signaling on bone mass was supported by the analysis of mice
with global gene deletion of 2-AR (2-AR/). These ani-
mals do not exhibit endocrine and metabolic abnormalities,
have a normal body weight, and exhibit a HBM phenotype
beginning at 6 mo of age due to an increase in bone formation
and a decrease in bone resorption (18).
However, a recent study by our group demonstrated that
young adult mice with global double-gene inactivation of 2A
and 2C adrenoceptors (2A/2C-AR/) also exhibit a pheno-
type of HBM that becomes more evident as the animals age
(from 40 to 120 days of age) despite exhibiting chronic
sympathetic hyperactivity and intact 2-AR (19). The 2-
adrenergic receptors (2-ARs) were characterized initially as
presynaptic autoreceptors that negatively regulate catechol-
amine release (13, 29). Later, it was shown that 2-ARs are not
restricted to presynaptic sites but can also have postsynaptic
locations and functions, which include the regulation of body
temperature, intraocular pressure, lipolysis, and pain percep-
tion (12, 28, 47). Three subtypes of 2-ARs have been identi-
fied: 2A-AR, 2B-AR, and 2C-AR (15, 32, 47). Hein et al.
(29) reported that the double blockage of 2A-AR and 2C-AR
in mice results in increased serum levels of norepinephrine
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(NE). In addition to the HBM phenotype, we found that
2A/2C-AR/ mice exhibit increased bone formation and
decreased bone resorption (19). Consistent with a previous
study that identified the presence of 2-AR isoforms in human-
derived bone cells (61), we demonstrated the mRNA expres-
sion of 2A-, 2B-, and 2C-AR in the bone of mice and in
osteoblast-like cells derived from the mouse calvarium
(MC3T3-E1 cells). By immunohistochemistry, we found that
2A-, 2B-, 2C-, and 2-AR are expressed in osteoblasts,
osteocytes, osteoclasts, and chondrocytes from fetal and adult
mice (19). Collectively, these findings raise the hypothesis that
2-AR may also mediate SNS signaling in the skeleton.
There is evidence that TH interacts with the SNS to control
several physiological processes. It is known that this interac-
tion is required for maximal thermogenesis, lipolysis, and
glycogenolysis (45). In addition, many of the clinical features
of hyperthyroidism, such as palpitations, tremor, sweating,
nervousness, weight loss, heat intolerance, stare, tachycardia,
and increased pulse pressure, mimic the manifestations of
excess -adrenergic activity and indicate that thyrotoxicosis
results in a state of hyperadrenergic stimulation (22, 49).
-Adrenergic blockage profoundly modifies the severity of
these symptoms, and their use in the management of hyper-
thyroidism is well established (34, 35, 50, 63, 64).
Considering the negative effects of thyrotoxicosis and SNS
activation on bone mass, we raised the hypothesis that TH may
also interact with the SNS to regulate bone metabolism. A
piece of evidence supporting this possible interaction is the fact
that the treatment of hyperthyroid patients with propranolol
corrects their hypercalcemia (53) and decreases their urinary
excretion of hydroxyproline, a biochemical marker of bone
resorption (6).
The aim of the present study was to investigate whether TH
interacts with the SNS to regulate bone mass and structure
during young adulthood in mice, a phase of important bone
mass accrual and growth. We observed that young adult
2A/2C-AR/ mice are resistant to the deleterious effects of
thyrotoxicosis on bone. These findings strongly suggest that
adrenergic signaling modulates TH actions in the bone.
MATERIALS AND METHODS
Animal maintenance and manipulation. A cohort of female con-
genic 2A/2C-AR-knockout (KO) mice in a C57BL/6J (B6) back-
ground and their wild-type (WT) controls were studied from 40 to 123
days of age, a phase of important bone mass accrual and growth (25).
The animals were considered young adults, since the pubertal matu-
ration in B6 female mice begins when serum estradiol increases by
day 26 after birth and is complete when vaginal opening occurs by day
31 (2). Animals received intraperitoneal injections of T3 (Sigma-
Aldrich, Munich, Germany) in a daily dose that corresponds to 10
times its physiological dose (10  T3  3.5 g·100 g body
wt1·day1) and is known to induce bone loss (21). T3 injections
were administered every day, at the same time each day. Animals
(n  7 animals/group) were treated for 12 wk. Body weight was
measured every week, and the amount of hormone administered was
adjusted according to the changes in body weight to maintain the
proper dosage. All experimental procedures were performed in accor-
dance with the guidelines of the Standing Committee on Animal
Research of the University of Sao Paulo (protocol no. 065-17/02),
which approved the study.
Serum levels of T3, thyroxine, and IGF-I. At the end of the
experimental period the animals were euthanized, and the blood was
collected. Serum levels of total thyroxine (T4) and T3 were measured
using radioimmunoassay commercial kits (RIA-gnost T4 and RIA-
gnost T3; CIS Bio International, Schering, Paris, France). Serum
IGF-I levels were measured by RIA (Diagnostic System Laboratories,
Webster, TX).
Femur and plasma levels of cathecholamines. For cathecolamine
extraction, the two whole femurs of each animal were crushed in a
steel mortar and pestle set (Fisher Scientific International, Hampton,
NH) precooled in dry ice. The crushed bones were weighed and
homogenized in 1.5 ml of cold 0.1 M perchloric acid containing
0.02% sodium pyrosulfite (Na2S2O5) and 0.7 nM 3,4-dihydroxyben-
zylamine hydromide as an internal standard. The homogenates were
kept at 4°C overnight and centrifuged at 10,000 rpm for 50 min at
4°C. The supernatants were stored at 80°C until they were assayed
for NE and epinephrine (EP). Femur and plasma levels of cathe-
cholamines were measured by HPLC using ion-pair reverse-phase
chromatography coupled with electrochemical detection (0.5 V), as
described previously (40, 42).
Determination of areal bone mineral density by dual-energy X-ray
absorptiomettry. Areal bone mineral density (aBMD) was measured
using the pDXA Sabre Bone Densitometer and the pDXA Sabre
Software version 3.9.4 (Norland Medical Systems, Fort Atkinson,
WI), both of which were especially designed for small animals. The
research mode scan option was used for the measurements. Pixel
spacing for the scan was set to 0.5  0.5 mm and the scan speed to
4 mm/s. To limit the scan area, which allows the scans to be
performed in a higher-resolution mode, the scans were performed
from the first lumbar vertebra to the hindlimbs. The regions of interest
for analysis were 1) the hind body, which includes the lumbar spine,
pelvic bones, and hindlimbs; 2) lumbar vertebrae (L1–L6); 3) both
femurs; and 4) both tibias. Taking into account the possibility of bone
mass differences between the left and right limbs as a result of
functional bilateral asymmetry (20), the aBMD of femur and tibia was
expressed as the mean of the left and right limbs for each animal. For
the scans, the animals were anesthetized with a ketamine and xylazine
cocktail (10 and 30 mg/kg body wt) and scanned in the prone position.
The animals were subjected to a basal scan and to scans after 4 and 12
wk of treatment.
Microcomputed tomography analysis. The microarchitecture of the
femur and lumbar vertebra (L6) was investigated using a microcom-
puted tomography (CT) unit (SkyScan 1172; SkyScan, Aartselaar,
Belgium) in which the samples were rotated through 360° at a rotation
step of 0.5°. The X-ray settings were standardized to 100 kV for the
baseline bone specimens, with an exposure time of 590 (ms). A
0.5-mm-thick aluminum filter and a beam-hardening algorithm were
used to minimize beam-hardening artifacts. The registered data sets
were segmented into binary images. The two- (2D) and three-dimen-
sional (3D) measurements were obtained with the CTAn version 1.5
(SkyScan). The distal metaphysis of the femur and the vertebral body
of L6 were selected as the regions of interest for the trabecular bone
analysis. The following 3D structural parameters were determined
from 180 and 210 transverse femoral and vertebral CT slices,
respectively: trabecular bone volume (BV/TV), trabecular thickness
(Tb.Th), trabecular number (Tb.N), trabecular separation (Tb.Sp),
trabecular porosity (Tb.Po), structure model index (SMI), trabecular
pattern factor (Tb.PF) and volumetric bone mineral density (vBMD).
Morphometric variables of cortical bone were measured in the fem-
oral diaphysis and in the vertebral body (170 and 70 transverse CT
slices) from the distal limit of the pedicles until the distal growth plate.
The cortical thickness (Ct.Th), tissue area (T.Ar), cortical area
(Ct.Ar), medullary area (Ma.Ar), cortical bone volume (Ct.BV), and
the polar moment of inertia (MMI) were measured in 2D cross-
sectional images. The cortical porosity (Ct.Po) and vBMD were
measured in 3D. To guarantee that the same bone regions were
measured in every sample, the number of transverse CT slices per
sample was calculated accordingly to the respective bone length
(femur or vertebra).
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Three-point bending test. The right femurs were tested in an Instron
testing machine (Model 3344; Instron, Norwood, MA). Fresh-frozen
bones were thawed to room temperature (22°C). The anterior cortex at
the middiaphysis of the femur was placed in compression and the
posterior cortex in tension during the test. The lower support points
were separated by an span of 50% of the femoral length (femur
length/2). A constant displacement rate of 0.03 mm/s was applied
until the bone fractured. Fracture was taken as the complete loss of
load-carrying ability. To stabilize the specimen, a small preload (5%
of the average maximal load) was applied before actual testing.
During the bending test, load displacement data were collected by a
computerized data acquisition system at a sampling rate of 80 Hz. The
biomechanical properties evaluated were the maximum load [a mea-
surement of the maximum force that the bone withstood before
fracture (N)], ultimate load [the load at the fracture point (N)],
resilience [a measurement of the ability of a bone to suffer elastic
deformity (J)], Young’s modulus (mPa), and stiffness (N/mm) (the
last two of which are measurements of the extrinsic rigidity of the
bone tissue).
Real-time PCR. Expression of 2A-AR, 2C-AR, 2-AR, 1-AR,
receptor activator of nuclear factor-	B (RANK), RANK ligand
(RANKL), and osteoprotegerin (OPG) were determined by real-time
PCR, as described previously (14) in the whole tibia. Briefly, the total
RNA was extracted using Trizol (Invitrogen, Carlsbad, CA), follow-
ing the manufacturer’s instructions. Total RNA was reverse tran-
scribed using RevertAid-H-Minus M-MuLV Reverse Transcriptase
(Fermentas, Hanover, MD) to synthesize the first-strand cDNA, which
was used as a template. SYBR Green Super Mix (Applied Biosys-
tems, Warrington, UK) was used for the real-time PCR using the ABI
Prism 7500 sequence detector (Applied Biosystems, Foster City, CA).
All primers used in this study [2A-AR  forward (F): CGC AGG
CCA TCG AGT ACA A and reverse (R): GAT GAC CCA CAC GGT
GAC AA (NM_007417.3); 2C-AR  F: CAT GGG CGT GTT CGT
ACT GT and R: CAG GCC TCA CGG CAG ATG (NM_007418.3);
1-AR  F: TCG TCC GTC GTC TCC TTC TAC and R: ACA CCC
GCA GGT ACA CGA A (NM_007419); 2-AR  F: GCC ACG
ACA TCA CTC AGG AAC and R: CGA TAA CCG CAC TGA GGA
TGG (NM_007420); RANK  F: TCT GCA GCT CTT CCA TGA
CAC T and R: CGA TGA GAC TGG GCA GGT AAG
(NM_009399); RANKL  F: GGC CAC AGC GCT TCT CAG and
R: GAG TGA CTT TAT GGG AAC CCG AT (NM_011613.2);
OPG  F: AGT CCG TGA AGC AGG AGT G and R: CCA TCT
GGA CAT TTT TTG CAA A (NM_U94331); 18S  F: GTA ACC
CGT TGA ACC CCA TT and R: CCA TCC AAT CGG TAG TAG
CG (M_11188); -actin  F: AAG ATT TGG ACC ACA CTT TCT
ACA and R: CGG TGA GCA GCA CAG GGT (NM_031144)] were
synthesized (Integrated DNA Technologies, Coralville, IA) specifi-
cally for real-time PCR using the Primer Express software (Applied
Biosystems). All CT values were normalized using an internal control:
18S or -actin mRNA. Both internal controls were validated for this
study, showing to be stable (their expression did not vary due to mice
lineage or T3 treatment). Relative gene expression quantification was
assessed by the 

CT method, as described previously by Livak (36).
The final values for samples are reported as fold induction relative to
the expression of the control, with the mean control value being
arbitrarily set to 1.
Calvaria-derived osteoblastic cell growth. Primary mouse osteo-
blastic cells were obtained by sequential enzyme digestion of excised
calvarial bones from neonatal WT and 2A/2C-AR/ mice, using 1%
trypsin and 1% collagenase in -MEM (Gibco BRL, Paisley, UK).
Osteoblasts were initially seeded at a density of 104 cells/well in
24-well plates and cultured in growth media containing -MEM
(Invitrogen) supplemented with 10% FBS (Gibco) and 1% penicillin-
streptomycin (Gibco). After 72 h (day 0), the culture medium was
changed to the differentiation medium, growth media were supple-
mented with 50 g/ml ascorbic acid (Sigma, St. Louis, MO) and 10
mM -glycerophosphate (Sigma), and the treatment with T3 (108 M)
and/or clonidine (CLO; 106 M) was initiated. Medium was changed
every 3 days. The cells were collected on day 0 and after 3, 6, and 9
days of treatment to determine the cell number and viability by direct
counting with a Neubauer Chamber (Improve Neubaur). Cell viability
was determined by the Trypan blue exclusion method, with cells
suspended in 0.4% Trypan blue dye (1:2 dilution; Gibco-BRL, Grand
Island, NY). Cells were assayed in quadruplicates.
Statistical analysis. Results are presented as means  SE. Two-
way analysis of variance was used to compare TH effects in WT and
KO mice and cells and was always followed by Tukey’s test to detect
differences between groups. The unpaired Student t-test was used for
pairwise comparisons of the groups. For all tests, significance was
defined as P  0.05. For statistical analyses, we used the GraphPad
Instat software package (GraphPad Software, San Diego, CA).
RESULTS
Sympathetic hyperactivity and induction of a thyrotoxic state
in 2A/2C-AR/ mice. We evaluated the effect of daily admin-
istration of 10 times the physiological dose of T3 for 12 wk on
bone of WT and 2A/2C-AR/ mice, which is an animal
model of chronic elevated sympathetic tone. T3 treatment
increased the serum concentration of T3 19-fold and conse-
quently decreased T4 serum levels 10- and 11-fold in WT and
KO mice, respectively (Table 1), which reflects TSH inhibition
by negative feedback (68). Serum T3 levels were not different
between T3-treated and untreated WT and KO mice; however,
untreated KO mice presented 31% higher serum T4 levels than
untreated WT mice. As expected, we observed that plasma
levels of NE and EP were higher in 2A/2C-AR/ mice
compared with WT mice (Fig. 1, A and B). Accordingly, the
femur concentration of NE was 96% higher in the bones of KO
mice compared with WT mice (Fig. 1C), whereas EP bone
concentration was not different between WT and KO mice.
Interestingly, T3 treatment decreased NE and EP plasma levels
(by 37 and 62%, respectively) only in WT mice (Fig. 1, A and
B), whereas T3 decreased NE concentration (by 53%) only in
the bones of 2A/2C-AR/ mice (Fig. 1C), bringing the bone
NE concentration of KO mice to the level of WT mice (KO 
T3  WT). Corroborating previous studies that reported car-
diac hypertrophy in conditions of thyrotoxicosis, T3 treatment
significantly and equally increased heart mass in WT (WT 
1.07  0.02 vs. WT  T3  1.35  0.11, P  0.05) and KO
Table 1. T3, T4, and IGF-I serum levels in WT and
2A/2C-AR/ mice
Treatment (Animal) Saline T3 P Value
T3
WT 0.37  0.07 7.00  0.6 0.0001
KO 0.39  0.02 7.32  0.5 0.0001
P value NS NS
T4
WT 27.6  3.1 2.7  0,4 0.0001
KO 36.2  2.8 3.2  0.5 0.0001
P value 0.05 NS
IGF-I
WT 57.8  2.1 56.4  3.4 NS
KO 53.5  2.3 66.6  2.7 0.05
P value NS NS
Data are presented as means  SE and in ng/ml (n  7/group). T3,
3,3=,5-triiodo-L-thyroxine; T4, thyroxine; 2A/2C-AR, 2A/2C-adrenoceptor;
WT, wild type; KO, knockout; NS, nonsignificant. Significance between the
groups was determined by 2-way ANOVA followed by Tukey’s test.
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animals (KO  1.16  0.02 vs. KO  T3  1.46  0.01, P 
0.05), which confirms the toxicity of the regimen of T3 treat-
ment used in this study. According to previous studies that
applied the same dose (66) or fourfold (57) the dose of T3 used
in the present study, body weight and body length were not
affected by TH administration in WT and KO animals. How-
ever, BW was significantly higher (13%) in KO mice during
the whole experimental period (P  0.01).
TH effects on serum levels of IGF-I. Since there is evidence
that the growth hormone-IGF-I axis may mediate the adrener-
gic signaling (9, 48) and TH actions in bone (31, 33), we
measured serum levels of IGF-I, which were significantly
increased (24%) by T3 treatment only in 2A/2C-AR/ mice
and not in WT mice (Table 1).
TH effects on the aBMD of 2A/2C-AR/ mice. As pre-
dicted, thyrotoxicosis was detrimental to the aBMD of WT
mice, significantly impairing bone mass acquisition in all
skeletal sites evaluated (Fig. 2). The aBMD of the hind body
(lumbar spine, pelvis, and hindlimbs), lumbar vertebrae (L1–
L6), femur, and tibia of WT mice treated with T3 for 12 wk was
11, 14, 13, and 9% lower, respectively, compared with euthy-
roid WT mice. Surprisingly, the bones of 2A/2C-AR/ mice
were found to be resistant to the osteopenic effects of TH
excess, as the supraphysiological dose of T3 had no effect on
the aBMD of KO mice. This critical finding strongly suggests
that TH interacts with the SNS to regulate bone mass.
TH effects on the bone microarchitecture of 2A/2C-AR/
mice. The CT data of the trabecular bone structure of the
distal methaphysis of the femur (Fig. 3, A–H) support the
dual-energy X-ray absorptiometry (DEXA) findings. T3 treat-
ment significantly decreased BV/TV (72%), Tb.N (62%),
Tb.Th (19%), and vBMD (8%) and increased Tb.Sp (68%),
Tb.Po (9%), and Tb.Pf (77%) in WT mice. On the other hand,
these parameters were not affected by T3 treatment in 2A/2C-
AR/ mice, except for Tb.N (Fig. 3B), which was also
decreased by T3 in KO mice (30%). The comparison of WT vs.
KO mice shows higher femoral Tb.N in 2A/2C-AR/ animals
(Fig. 3B). Considering the T3-treated animals, we found higher
BV/TV, Tb.N, Tb.Th, and vBMD and lower Tb.Sp, Tb.Po, and
Tb.Pf in KO vs. WT mice, which strengthens the resistance of
the femoral trabecular bone of KO mice to the deleterious
effects of thyrotoxicosis. The trabecular bone of the vertebra
was less sensitive to the TH effects (Fig. 3, I–P). T3 treatment
significantly decreased trabecular vBMD (14%) only in WT
(Fig. 3P) and decreased BV/TV (29%) only in KO mice (Fig.
3I). According to previous findings (19), vertebral BV/TV
(Fig. 3I) was higher and vertebral Tb.Po (Fig. 3M) and SMI
(Fig. 3O) were lower in untreated WT vs. untreated KO mice.
The CT analysis of the cortical bone of the femoral diaphysis
demonstrated that T3 treatment decreased Ct.Th (22%), T.Ar
(25%), Ct.Ar (25%), Ma.Ar (49%), and Ct.BV (25%) and
increased Ct.Po (9%) only in WT mice (Fig. 4, A–F). The
comparison of WT vs. KO mice shows higher cortical vBMD
(Fig. 4H) in 2A/2C-AR/ animals, which corroborates the
DEXA findings. Taking into account the T3-treated animals,
we found higher femoral Ct.Th, T.Ar, Ct.Ar, Ma.Ar, and
Ct.BV and lower Ct.Po in KO vs. WT mice, which supports the
resistance of the femoral cortical bone of KO mice to the
deleterious effects of thyrotoxicosis. The cortical bone of
vertebra (L6) was negatively affected by thyrotoxicosis in both
WT and KO mice. T3 treatment reduced Ct.Th (22% in WT
and 32% in KO), Ct.Ar (46% in WT and 35% in KO), Ct.BV
(46% in WT and 38% in KO), and MMI (45% in WT and 38%
in KO) in WT and 2A/2C-AR/ animals (Fig. 4, I–K, M, and
Fig. 1. Effect of thyroid hormone excess on plasma and bone levels of
norepinephrine (NE) and epinephrine (EP). A and B: plasma levels. C and D:
femoral levels. A and C: NE. B and D: EP. Animals were treated with a
supraphysiological dose of 3,3=,5-triiodo-L-thyronine (T3; 3.5 g·100 g body
wt1·day1) or saline for 12 wk. Treatment started when the animals were 40
days old. Values are expressed as the means  SE (n  7/group). *P  0.05
vs. the respective saline-treated animals [wild type (WT) vs. WT  T3 or
knockout (KO) vs. KO  T3]. Nos. above the bars indicate the P values for
differences between WT and KO mice, as indicated.
Fig. 2. Effect of thyroid hormone excess on the areal bone mineral density
(aBMD) of WT and 2A/2C-adrenoceptor (AR)/ mice, as determined by
dual-energy X-ray absorptiometry. A: hind body (includes L1–L6, pelvic
bones, and hindlimbs). B: lumbar vertebrae (L1–L6). C: femur. D: tibia.
Animals were treated with a supraphysiological dose of T3 (3.5 g·100 g body
wt1·day1) or saline for 12 wk. Treatment started when the animals were 40
days old. Values are expressed as means  SE (n  7/WT and KO group).
*P  0.05 and **P  0.01, WT vs. WT  T3; P  0.05 and P  0.01,
WT vs. KO and WT  T3 vs. KO  T3.
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O). However, T3 treatment reduced T.Ar (45%) and increased
Ct.Po (14%) only in the vertebra of WT animals. Corroborating
the DEXA findings, Ct.BV and cortical vBMD of L6 were
higher in the KO mice (Fig. 4, M and P, respectively).
TH effects on the bone biomechanical parameters of 2A/2C-
AR/ mice. In accord with DEXA and CT findings, the
three-point bending test showed that the femoral maximum
load, ultimate load, and stiffness were decreased significantly
by T3 treatment only in WT mice and not in 2A/2C-AR/
animals (Fig. 5, A–C). In addition, we found lower femoral
maximum load, ultimate load, stiffness, young’s modulus, and
resilience in WT  T3 than in KO  T3 mice (Fig. 5). No
significant differences were found in any of the biomechanical
parameters tested between untreated WT and KO mice. Alto-
gether, these data indicate a resistance of the KO mice to the
deleterious effects of thyrotoxicosis also on the biomechanical
features of the femur.
Effect of T3 treatment on the gene expression of the RANKL/
RANK/OPG system. To further investigate a possible interac-
tion between TH and the SNS in the bone, we evaluated the
effect of T3 on the gene expression of the RANKL/RANK/
OPG system, which plays a pivotal role in bone remodeling by
regulating osteoclast formation and activity (67). T3 treatment
had no effect on the expression of RANK or RANKL (Fig. 6,
A and B) in either WT or KO animals. On the other hand, OPG
mRNA expression was decreased (66%) by T3 treatment in
WT mice and increased (2-fold) by T3 treatment in KO animals
(Fig. 6C), which may partially explain the osteopenic effect of
T3 in WT mice but not in KO mice. Surprisingly, OPG mRNA
expression was shown to be lower in KO mice vs. WT mice.
Effect of T3 treatment on the expression of adrenoceptors in
bone. T3 treatment increased the mRNA expression of 1-AR
in the bone of 2A/2C-AR/ mice by 40% (P  0.05) but did
not increase expression in the bone of WT animals (Fig. 7A).
On the other hand, T3 treatment decreased 2-AR mRNA
expression by 33% in WT but not in KO mice (Fig. 7B). In WT
animals, T3 treatment had no effect on the bone expression of
2A-AR mRNA (Fig. 7C) but decreased 2C-AR mRNA ex-
pression significantly by 30% (Fig. 7D). There were no signif-
icant differences between WT and KO animals regarding the
mRNA expression of adrenoceptors in the bone.
Calvaria-derived osteoblastic cells from WT and 2A/2C-
AR/ respond differently to T3 and CLO. We tested the effect
of T3 treatment on cell growth of osteoblasts derived from WT
and 2A/2C-AR/ mice (Fig. 8A). T3 (108 M) decreased the
growth of WT cells significantly after 3, 6, and 9 days of
treatment, which corroborates previous studies (5, 65, 70). On
the other hand, in KO cells, T3 treatment for 3 days had no
effect on cell growth, whereas 6 and 9 days of treatment
increased this parameter. Compared with WT cells, untreated
KO cells grew significantly less during the whole experimental
period (Fig. 8A), suggesting that 2A-AR and/or 2C-AR have
Fig. 3. Effect of thyroid hormone excess on the structural parameters of the trabecular bone of the distal metaphysis of the femur and vertebral body of L6 in
WT and 2A/2C-AR/ mice assessed by microcomputed tomography (CT). A–H: distal metaphysis of the femur. I–P: vertebral body of L6. Animals were
treated with a supraphysiological dose of T3 (3.5 g·100 g body wt1·day1) or saline for 12 wk. Values are expressed as means  SE (n  6/group). *P 
0.05, **P  0.01, and ***P  0.001 vs. the respective saline-treated animals (WT vs. WT  T3 or KO vs. KO  T3). Nos. above the bars indicate the P values
for differences between WT and KO mice, as indicated. BV/TV, trabecular bone volume; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, trabecular
speculation; Tb.Po, trabecular porosity; Tb.PF, trabecular pattern function; SMI, structure model index; vBMD, volumetric bone mineral density.
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a function on the regulation of this process. Next, WT and KO
cells were treated with CLO, an unspecific 2-AR agonist,
alone or combined with T3 to test whether 2-adrenoceptors
are functional in osteoblastic cells and whether their activation
modifies the responsiveness of these cells to T3. In WT cells
(Fig. 8B), CLO or T3 treatment for 3, 6, and 9 days decreased
cell growth significantly, whereas the combination of both
agents promoted a higher decrease than T3 alone, in an additive
manner. In contrast, in KO cells (Fig. 8C), CLO increased cell
growth after 3, 6, and 9 days of treatment. T3 also increased
KO cell growth, but not as much as CLO and only after 6 and
9 days of treatment. The combination of both agents showed
Fig. 4. Effect of thyroid hormone excess on the structural parameters of the cortical bone of the femoral midshaft and vertebral body of L6 in WT and
2A/2C-AR/ mice assessed by CT. A–H: femoral midshaft. I–P: vertebral body of L6. Animals were treated with a supraphysiological dose of T3 (3.5 g·100
g body wt1·day1) or saline for 12 wk. Values are expressed as means  SE (n  6/group). *P  0.05 and **P  0.01 vs. the respective saline-treated animals
(WT vs. WT  T3 or KO vs. KO  T3). Nos. above the bars indicate the P values for differences between WT and KO mice, as indicated. Ct.Th, cortical
thickness; T.Ar, tissue area; Ct.Ar, cortical area; Ma.Ar, medullary area; Ct.BV, cortical bone volume; Ct.Po, cortical porosity; MMI, polar moment of inertia.
Fig. 5. Effect of thyroid hormone excess on
the biomechanical parameters of the femur
in WT and 2A/2C-AR/ mice. Data were
assessed by means of the 3-point bending
test. Animals were treated with a supraphysi-
ological dose of T3 (3.5 g·100 g body
wt1·day1) or saline for 12 wk. Values are
expressed as means  SE (n  6/group).
*P 0.05 and **P 0.01 vs. the respective
saline-treated animals (WT vs. WT  T3).
Nos. above the bars indicate the P values for
differences between WT  T3 and KO  T3
mice.
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that the effect of T3 was not modified by CLO in KO cells;
however, T3 significantly attenuated the effect of CLO on cell
growth after 3 and 6 days of treatment. Cell viability, assessed
by Trypan blue exclusion, was always 90% and was not
affected by T3 or CLO treatment at any time point tested in
either cell lineage. Since cell viability was not affected by both
agents, it is likely that their effects in cell growth were mainly
the result of an effect in cell proliferation rather than in cell
death.
DISCUSSION
To investigate whether the osteopenic effects of TH excess
could depend on SNS activation, we evaluated whether the
thyrotoxicosis-induced osteopenia is intensified in 2A/2C-
AR/ mice, which exhibit elevated plasma NE and intact
2-AR (29). Interestingly, these mice exhibit a phenotype of
HBM despite their elevated sympathetic tone, which is strong
evidence that 2-AR is not the unique adrenoceptor involved in
the control of bone turnover and raises the hypothesis that
2-ARs may also mediate SNS signaling in the skeleton (19).
Treatment with the supraphysiological dose of T3 for 12 wk
promoted the characteristic effects of thyrotoxicosis (30, 54,
55), including cardiac hypertrophy both in WT and KO mice,
and a generalized decrease in aBMD in WT mice determined
by DEXA. In contrast, a surprising and very interesting finding
was that 2A/2C-AR/ mice were resistant to the thyrotoxico-
sis-induced osteopenia, as the supraphysiological dose of T3
had no effect on their bone mass. The CT analysis substan-
tiates the resistance of 2A/2C-AR/ mice to the osteopenic
effects of TH excess. As expected, thyrotoxicosis negatively
affected most of the microarchitectural features of the distal
metaphysis trabecular bone and midshaft cortical bone of the
femur in WT but not in 2A/2C-AR/ mice. These findings
were accompanied by T3-induced declines in the biomechani-
cal properties (maximum load, ultimate load, and stiffness) of
the femur only in WT and not in KO mice. Corroborating
previous studies that show that TH preferentially affects fem-
oral but not vertebral bone (26, 44, 51, 59), the microstructural
parameters of the trabecular bone of L6 were barely affected by
T3 treatment. However, the trabecular vBMD of L6, deter-
mined by CT, was decreased significantly by TH treatment
only in WT mice and not in KO mice, which is in agreement
with the aBMD findings determined by DEXA. On the other
hand, the cortical bone of L6 was negatively affected by
thyrotoxicosis both in WT and KO mice. Nevertheless, it was
slightly more affected by TH in WT than in KO mice, since T3
treatment decreased T.Ar and increased Ct.Po of L6 in WT but
not in KO mice. Altogether, these results strongly suggest that
TH excess depends on intact 2-AR signaling to negatively
regulate bone mass, structure, and biomechanical resistance,
especially in the femur. The fact that the double-gene deletion
of 2A- and 2C-AR prevented the negative effects of TH in the
femoral cortical bone but not in the vertebral cortical bone
suggests that the TH-SNS interaction may vary depending on
the skeletal site. In fact, several studies show that the TH-
adrenergic interrelationships are by no means uniform from
tissue to tissue, from organ to organ, or in different regions of
the same organ (56).
Fig. 6. Effect of thyroid hormone excess on the relative mRNA expression of the receptor activator of nuclear factor-	B (RANK)/RANK ligand
(RANKL)/osteoprotegerin (OPG) system (A–C) in WT and 2A/2C-AR/ mice, as determined by real-time PCR analysis. Animals were treated with a
supraphysiological dose of T3 (3.5 g·100 g body wt1·day1) or saline (-) for 12 wk. mRNA expression was determined by real-time PCR analysis. Values
are expressed as means  SE (n  6/group). *P  0.05 and **P  0.01 vs. the respective saline-treated animals (WT vs. WT  T3 or KO vs. KO  T3). Nos.
above the bars indicate the P values for differences between WT and KO, as indicated.
Fig. 7. Effect of excess thyroid hormone on the relative mRNA expression of
adrenoceptors. A and B: WT vs. KO mice. C and D: WT mice. Animals were
treated with a supraphysiological dose of T3 (3.5 g·100 g body wt1·day1)
or saline (-) for 12 wk. mRNA expression was determined by real-time PCR
analysis. Values are expressed as means  SE (n  6/group). *P  0.05 and
**P 0.001 vs. the respective saline-treated animals (WT vs. WT T3 or KO
vs. KO  T3). Nos. above the bars indicate the P values for differences
between WT and KO, as indicated.
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We also evaluated the effect of TH on the RANK/RANKL/
OPG system. RANKL, expressed by the osteoblasts, is the
ligand of RANK (an osteoclast plasma membrane receptor)
and the main inducer of osteoclast formation, function, and
survival (67). OPG, also expressed by the osteoblasts, is the
natural inhibitor of osteoclastic activity, since it binds RANKL
and thereby impairs RANKL/RANK association. T3 signifi-
cantly increased OPG mRNA expression in 2A/2C-AR/
mice and decreased OPG mRNA expression in WT mice. This
finding is consistent with the osteopenic effect of T3 in WT but
not in 2A/2C-AR/ mice and suggests that the RANK/
RANKL/OPG system may partially mediate TH actions in the
bone. Additionally, it suggests that this mediation is affected
by modifications in SNS signaling, which in turn reinforces a
TH-SNS interaction to regulate bone physiology.
The interaction of TH with the SNS is normally complex and
may occur at multiple levels (56). TH generally potentiates
-AR signals, and it occurs in different ways, depending on the
tissue or organ (56). Certainly, one mechanism whereby TH
can alter these signals is by modifying the expression of
adrenoceptors (7). Considering this mechanism, we first eval-
uated whether TH could modify the mRNA expression of 1-
and 2-AR in the bone. We found that TH decreased 2-AR
mRNA expression only in the bone of WT mice. In contrast, T3
treatment increased 1-AR mRNA expression only in the bone
of 2A/2C-AR/ mice. These findings once more show that the
absence of 2A-AR and/or 2C-AR alters the way that bone
responds to thyrotoxicosis, supporting the hypothesis of a
TH-SNS interaction to regulate bone physiology. It is well
known that TH can modify the number of -ARs, but again,
this effect is not the same in all tissues, nor does it include all
isoforms (7, 52). As a consequence of thytoxicosis, for exam-
ple, the number of -ARs has been shown to be increased in rat
heart muscle and brown adipose tissue, decreased in rat liver,
and increased or not changed in rat white adipose tissue and
human leukocytes (7). It is noteworthy that 1-AR KO mice
exhibit low bone mass, which suggests that this receptor
mediates the anabolic actions of the SNS in the bone (11). In
fact, a recent study indicates that 1-AR exerts predominant
and opposite effects of 2-AR on bone remodeling through
both systemic and local factors (48). Moreover, evidence
indicates that the anabolic effects of 1-AR signaling are
partially mediated by systemic IGF-I, which should be upregu-
lated by 1-AR activation (48). Interestingly, in the present
study, we found that TH treatment increased IGF-I serum
levels only in 2A/2C-AR/ mice, which exhibited elevated
1-AR mRNA expression. Thus, the positive effect of T3
treatment on 1-AR mRNA expression and on IGF-I serum
levels in 2A/2C-AR/ mice, but not in WT mice, may
partially explain the resistance of KO mice to the TH-induced
osteopenia.
We also found that T3 treatment reduced 2C-AR mRNA
expression but not 2A-AR mRNA expression in the bone of
WT mice. The effect of TH on -ARs has been much less
investigated than on -ARs. In general, it seems that TH
decreases the expression of -ARs (7), which corroborates our
findings. Besides bone, it was observed in the heart, liver, and
white adipose tissue (7). The physiological implication of the
T3-induced reduction in 2C-AR mRNA expression observed
in the present study cannot be inferred at this point. However,
the thyrotoxicosis-induced modulation of 1-AR, 2-AR, and
2C-AR mRNA expression observed in the bone suggests that
these adrenoceptors may be sites of interaction between TH
and the SNS to regulate bone structure and physiology. Nev-
ertheless, it is important to consider that the adrenoceptors
themselves are only two of many sites of TH-SNS interaction.
Furthermore, T3-induced modifications in adrenoceptors are
usually modest or nonexistent and thus generally cannot ac-
count for the T3-induced modifications in the SNS responsive-
ness (56). Usually, modulations of more distal cellular effec-
tors are shown to be responsible for the TH-induced changes in
the catecholamine responsiveness (56). It is possible that these
downstream effectors may have been modified by the disrup-
tion of 2-AR signaling in bone cells, which remains to be
investigated.
Fig. 8. Effect of T3 and clonidine (CLO) on osteoblastic cell growth. A: effect
of T3 on WT and 2A/2C-AR/ cells. B: effect of T3 and/or CLO on WT cells.
C: effect of T3 and/or CLO on 2A/2C-AR/ cells. Cells were cultured in
osteogenic media and treated with 108 M T3 and 106 M CLO for 3, 6, or 9
days. Each point represents means  SE (n  4). *P  0.01 and **P  0.001
vs. untreated WT cells; P  0.05 vs. untreated 2A/2C-AR/ cells; XP 
0.01 vs. all groups. Nos. above the bars indicate the P values for differences
between the indicated groups.
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Another point of TH-SNS interaction is the central sympa-
thetic outflow. TH regulates the sympathetic nerve activity, and
therefore, it modulates serum and tissue levels of cat-
echolamines (38). Regardless of a hyperadrenergic state in
thyrotoxicosis, there is a reduction of the central sympathetic
outflow, which results in reduced serum levels of NE (38, 62).
This paradox is also observed in hypothyroid patients, who
clinically manifest signs of decreased adrenergic stimulation
but can be expected to have increased serum levels of EP, NE,
and its metabolites (35). Therefore, we evaluated plasma and
bone levels of cathecolamines. As predicted, NE and EP were
significantly elevated in the plasma of 2A/2C-AR/ mice,
which correlates with the fact that 2A- and 2C-AR are the
main autoreceptors responsible for limiting NE release from
the sympathetic nerves and from chromaffin cells in the adrenal
medulla (32), respectively. As expected, T3 decreased plasma
NE in WT mice. In contrast, this effect was not observed in
2A/2C-AR/ mice, suggesting that 2-ARs are important for
mediating the TH effects on the sympathetic outflow. Interest-
ingly, bone concentration of NE was significantly elevated in
2A/2C-AR/ mice and was reduced only by T3 treatment in
2A/2C-AR/ mice. The effect of T3 on NE tissue levels also
varies depending on the tissue. For example, thyrotoxicosis
was shown to increase or not change NE concentration in the
heart and to decrease NE levels in the cerebral cortex (37). In
general, the sympathomimetic features of thyrotoxicosis can-
not be explained by increased sympathetic outflow, turnover,
or cathecolamine release. On the other hand, TH generally
modifies the cellular responsiveness to SNS signals, which
overrides the inhibitory or stimulatory effect of thyrotoxicosis
or hypothyroidism, respectively, on the central SNS outflow
(22, 56). This may also occur in the bone, since plasma and
bone levels of NE could not explain the osteopenic effects of
thyrotoxicosis in WT mice.
To get insight on whether 2A-AR signaling can directly
modify bone responsiveness to TH, we evaluated the effect of
T3 on cell growth of calvaria-derived osteoblasts isolated from
WT and 2A/2C-AR/ mice. We first observed a lower cell
growth in 2A/2C-AR/ cells than in WT cells, suggesting that
2A-AR and/or 2C-AR signaling in osteoblasts may be im-
portant for this process. Accordingly, growth of WT cells was
decreased by CLO, an unspecific 2-AR agonist, whereas
growth of KO cells was increased by this agent. The response
of KO cells to CLO may be the result of a CLO-mediated
activation of 2B-AR, which was shown to serve functions in
peripheral tissues as well as in the CNS (32) and to be
expressed in bone cells, including osteoblasts (19). As ex-
pected, and corroborating previous studies (5, 65, 70), T3
decreased the growth of WT cells significantly. However,
following the pattern of T3 effects observed in vivo, this
negative effect of T3 was completely absent or reversed in
2A/2C-AR/ cells. Additionally, the combination of T3 with
CLO had an additive effect on the inhibition of WT cell
growth, whereas T3 attenuated the positive effect of CLO on
KO cell growth. Altogether, these findings suggest that a
TH-SNS interaction involving 2-AR signaling may occur in
osteoblasts to locally regulate bone physiology.
These in vivo results also suggest that nonneuronal 2-ARs
may be important to directly mediate SNS actions in the bone.
As mentioned before, 2-AR are classic autoreceptors (presyn-
aptic receptors that inhibit the exocytosis of their own neu-
rotransmitter) that inhibit NE or EP release from adrenergic
neurons (of the SNS and CNS) and from chromaffin cells (of
the adrenal medulla) to control the sympathetic tonus (58).
However, 2-ARs are also expressed as heteroreceptors on
nonadrenergic neurons in the peripheral and CNS. Heterore-
ceptors are presynaptic release-modulating receptors that are
activated by neurotransmitters from neighboring neurons (58).
As heteroreceptors, 2A-ARs can inhibit the release of several
neurotransmitters, including serotonin, GABA, and dopamine
(23). In addition to these presynaptic neuronal receptors (auto
and heteroreceptors), 2-ARs were also identified in many
nonneuronal cell types of the body (23), including osteoblasts,
osteocytes, osteoclasts, and chondrocytes (19, 61). Recently,
the Dbh promoter was used to drive expression of 2A-AR
exclusively in noradrenergic and adrenergic neurons. Dbh-2A
transgenic mice were crossed with 2A/2C-AR/ mice to
generate animals with selective expression of 2A-autorecep-
tors in adrenergic cells (24). The analysis of these mice
confirmed the importance of 2A-autoreceptors as presynaptic
inhibitory feedback receptors to control NE release but, more
importantly, showed that the majority of 2-AR effects were
mediated by 2-ARs in nonadrenergic neurons (heteroceptors)
or nonneuronal cells. In addition, studies have shown that
nonneuronal 2-ARs have essential roles in the body (23).
Considering all these features of 2-ARs, the TH-SNS inter-
actions to control bone physiology may be extremely complex
and may involve 2-autoreceptors, 2-heteroreceptors, and/or
2-ARs present in bone cells. Further studies are required to
identify the involvement of these 2-ARs subtypes in bone
physiology.
It is important to consider that our data are based on a global
gene deletion model that has its strengths and limitations (16).
The resistance of 2A/2C-AR/ mice to the thyrotoxicosis-
induced alterations in the bone mass, microstructure, and
biomechanical parameters provides strong evidence that TH
depends on the integrity of the SNS to control bone physiol-
ogy, which is an original and important finding. On the other
hand, global KO models make it difficult to discriminate direct
from indirect effects and the roles of a particular gene (16).
Therefore, our data do not clearly elucidate whether TH inter-
acts with the SNS at the CNS and/or at the local (bone) level.
Given the complexity of TH-SNS interaction to control other
physiological functions (56), it is much more likely that the
diverse bone responses of WT and KO mice to TH observed in
the present study are the result of both central and skeletal
SNS-TH interaction. The sites and mechanisms of this inter-
action are important points for future investigation. In vitro and
in vivo studies involving mice with specific deletions of 2-AR
subtypes in bone cells and also in adrenergic cells (autorecep-
tors and heteroreceptors) will be valuable tools to elucidate
these issues.
Another point to be considered is the life stage of the
animals. This study shows that TH depends on the integrity of
the SNS to regulate bone mass and structure during the young
adulthood of mice, a phase of important bone mass accrual.
The TH-SNS interaction during later stages of life may be
different and promote different effects on bone mass and
structure than those observed in the present study. This matter
is supported by evidence that the SNS signaling may vary
depending on the life stage. The study by Pierroz et al. (48), for
instance, suggests that 1-adrenergic signaling exerts a pre-
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dominant anabolic stimulus on bone during growth, whereas
2-adrenergic signaling predominantly regulates bone turnover
during aging.
In summary, the present study provides strong evidence that
TH interacts with the SNS to control bone mass and structure
in young adult mice. Nevertheless, the mechanisms underlying
this interaction and whether it occurs at the central and/or
skeletal level or whether the TH-adrenergic interrelationships
depend on 2-autoreceptors, 2-heteroreceptors, and/or non-
neuronal 2-ARs are important issues raised by this study that
need to be clarified in future studies. Finally, the present
findings offer new insights into the mechanisms through which
TH regulates bone mass, structure, and physiology.
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